Data Suggest That Men Should Resolve to Address Their BPH Symptoms in 2019
January 16, 2019
NeoTract Study Finds That Men Over 40 Are Not Aware that Delaying Treatment of Benign Prostatic Hyperplasia (BPH) Can Cause Permanent Bladder Damage...
Read More12-Month Results from Study of NeoTract’s UroLift® System for BPH in Men with an Obstructive Median Lobe Published in Prostate Cancer and Prostatic Diseases
December 14, 2018
PLEASANTON, Calif. – December 14, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in...
Read MoreNeoTract Announces Japanese Regulatory Approval for UroLift® System for Treatment of Enlarged Prostate
November 5, 2018
PLEASANTON, Calif. – November 5, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in...
Read MoreNeoTract Receives Phoenix 2018 Emerging Growth Company Award for Outstanding Industry Achievement
October 29, 2018
PLEASANTON, Calif. – October 29, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in...
Read MoreNeoTract Announces Data from New Real-World Study Demonstrating Excellent Results for UroLift® System Treatment for Enlarged Prostate
October 15, 2018
PLEASANTON, Calif. – Oct. 15, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the...
Read MoreNeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate
September 24, 2018
PLEASANTON, Calif. – Sept. 24, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in...
Read MoreNeoTract Announces Multiple Data Presentations from Studies of UroLift® System Treatment for Enlarged Prostate at the World Congress of Endourology
September 18, 2018
PLEASANTON, Calif. – Sept. 17, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in...
Read MoreNeoTract Announces Independent Analysis in UK Confirming Cost Effectiveness of UroLift® System Treatment for Benign Prostatic Hyperplasia (BPH)
June 8, 2018
WAYNE, PA – June 08, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of...
Read MoreNeoTract Announces American Urological Association (AUA) Recommendation of UroLift® System as a Standard of Care Option for the Treatment of Enlarged Prostate
May 18, 2018
PLEASANTON, Calif. – May 18, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE: TFX) focused on addressing unmet needs in the...
Read MoreNeoTract To Unveil New Clinical Data on the UroLift® System at American Urological Association 2018 Meeting
May 16, 2018
PLEASANTON, Calif. - May 16, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the...
Read More
